// App-Quantinova.ai

5522 : Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

Researchers

Presenter

  • Hyun Cheol Chung

Principal Investigators

  • Jan H. M. Schellens

  • Jean-Pierre Delord

  • Ruth Perets

  • Antoine Italiano

  • Ronnie Shapira-Frommer

  • Lyudmila Manzuk

  • Sarina Anne Piha-Paul

  • Jiangdian Wang

  • Susan Zeigenfuss

  • Scott K. Pruitt

  • Aurelien Marabelle

Medical Centers

  • Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands

  • Institut Claudius Regaud, Toulouse, France

  • Rambam Health Care Campus, Haifa, Israel

  • Institut Bergonie, Bordeaux, France

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Merck & Co., Inc., Kenilworth, NJ

  • Departement dInnovation Therapeutique et dEssais Precoces, Gustave Roussy, Villejuif, France

Locations

  • France

  • United States

  • Israel

  • Netherlands

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02628067

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved